766
Participants
Start Date
June 1, 2023
Primary Completion Date
May 31, 2028
Study Completion Date
May 31, 2031
Fluzoparib
Fluzoparib 50mg bid orally for 1 year.
Anastrozole
1mg, qd orally
Letrozole
2.5mg, qd orally
Exemestane
25mg, qd orally
Tamoxifen
10mg, bid orally
Toremifene
60mg, qd orally
Abemaciclib
150mg/100mg/50mg, bid orally for 2 years
LHRH agonist
Leuprorelin acetate, goserelin acetate
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
The First Hospital of China Medical University, Shenyang
RECRUITING
Liaoning Cancer Hospital & Institute, Shenyang
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai
RECRUITING
Shanghai First Maternity and Infant Hospital, Shanghai
RECRUITING
Northern Jiangsu People's Hospital, Yangzhou
RECRUITING
Affiliated Hospital of Nantong University, Nantong
RECRUITING
Fujian Medical University Union Hospital, Fuzhou
RECRUITING
Chongqing Cancer Hospital, Chongqing
RECRUITING
Sun Yat-sen University Cancer Center, Guangdong
RECRUITING
Guangdong Academy of Medical Sciences Guangdong Provincial People's Hospital, Guangzhou
RECRUITING
West China Hospital of Sichuan University, Chengdu
RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
RECRUITING
Ningbo Medical Center Lihuili Hospital, Ningbo
Fudan University
OTHER